Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen (PRADAII)
Pharmacokinetics, Safety and Efficacy of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen in Patients With Intolerance and/or Resistance to NRTIs, NNRTIs and RTV: A Pilot Study
Sponsor: Radboud University Medical Center
Terminated
due to introduction of another integrase inhibitor, recruitement was not feasible anymore.
Other terminated trials from Radboud University Medical Center
This PHASE2 trial investigates HIV-1 Infection and is currently terminated or withdrawn. Radboud University Medical Center leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Apr 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Radboud University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .